Literature DB >> 16741512

Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma.

Machteld M Tiemessen1, Tracey J Mitchell, Lisa Hendry, Sean J Whittaker, Leonie S Taams, Susan John.   

Abstract

Mycosis fungoides and its leukemic variant, Sezary syndrome, are the most common primary cutaneous T-cell lymphomas (CTCLs). In an ex vivo study, we investigated the percentage, phenotype, and suppressive function of CD4+CD25+ regulatory T cells (Tregs) from peripheral blood of CTCL patients. The percentage of Tregs did not differ significantly between patients and controls. Functional assays demonstrated a dichotomy in Treg function: in four out of 10 patients CD4+CD25+ T cells were incapable of suppressing autologous CD4+CD25- T-cell proliferation, whereas suppressive function was intact in the other six patients. Suppressive activity of Tregs inversely correlated with the peripheral blood tumor burden. T-plastin gene expression, used as a Sezary cell marker, confirmed that Sezary cells were heterogeneous for CD25 expression. Mixed lymphocyte reactions demonstrated that CD4+CD25- T cells from patients who lacked functional Tregs were susceptible to suppression by Tregs from healthy controls, and had not become suppressive themselves. Furthermore, we found reduced expression of Foxp3 in the CD4+CD25+ Tregs of these patients relative to the other six CTCL patients and controls. Our findings thus indicate a dysfunction of peripheral Tregs in certain CTCL patients, which correlates with tumor burden.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16741512      PMCID: PMC2621310          DOI: 10.1038/sj.jid.5700371

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  33 in total

Review 1.  Sézary syndrome: diagnostic criteria and therapeutic options.

Authors:  R Russell-Jones; S Whittaker
Journal:  Semin Cutan Med Surg       Date:  2000-06

2.  Molecular and flow cytometric analysis of the Vbeta repertoire for clonality assessment in mature TCRalphabeta T-cell proliferations.

Authors:  A W Langerak; R van Den Beemd; I L Wolvers-Tettero; P P Boor; E G van Lochem; H Hooijkaas; J J van Dongen
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

3.  Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy.

Authors:  Michael Nebozhyn; Andrey Loboda; Laszlo Kari; Alain H Rook; Eric C Vonderheid; Stuart Lessin; Carole Berger; Richard Edelson; Calen Nichols; Malik Yousef; Lalitha Gudipati; Meiling Shang; Michael K Showe; Louise C Showe
Journal:  Blood       Date:  2006-01-10       Impact factor: 22.113

4.  STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma.

Authors:  C Brender; M Nielsen; K Kaltoft; G Mikkelsen; Q Zhang; M Wasik; N Billestrup; N Odum
Journal:  Blood       Date:  2001-02-15       Impact factor: 22.113

5.  CD4+CD25high regulatory cells in human peripheral blood.

Authors:  C Baecher-Allan; J A Brown; G J Freeman; D A Hafler
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

6.  Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells.

Authors:  C A Piccirillo; E M Shevach
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

7.  Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population.

Authors:  L S Taams; J Smith; M H Rustin; M Salmon; L W Poulter; A N Akbar
Journal:  Eur J Immunol       Date:  2001-04       Impact factor: 5.532

8.  Coexpression of CD40 and CD40 ligand in cutaneous T-cell lymphoma (mycosis fungoides).

Authors:  M Storz; K Zepter; J Kamarashev; R Dummer; G Burg; A C Häffner
Journal:  Cancer Res       Date:  2001-01-15       Impact factor: 12.701

9.  Increased expression of a novel early activation surface membrane receptor in cutaneous T cell lymphoma cells.

Authors:  M Nikolova; A Tawab; A Marie-Cardine; M Bagot; L Boumsell; A Bensussan
Journal:  J Invest Dermatol       Date:  2001-05       Impact factor: 8.551

10.  Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function.

Authors:  M K Levings; R Sangregorio; M G Roncarolo
Journal:  J Exp Med       Date:  2001-06-04       Impact factor: 14.307

View more
  27 in total

Review 1.  [Update on extracorporeal photopheresis].

Authors:  U Just; R Knobler
Journal:  Hautarzt       Date:  2015-11       Impact factor: 0.751

2.  Guidelines on the use of extracorporeal photopheresis.

Authors:  R Knobler; G Berlin; P Calzavara-Pinton; H Greinix; P Jaksch; L Laroche; J Ludvigsson; P Quaglino; W Reinisch; J Scarisbrick; T Schwarz; P Wolf; P Arenberger; C Assaf; M Bagot; M Barr; A Bohbot; L Bruckner-Tuderman; B Dreno; A Enk; L French; R Gniadecki; H Gollnick; M Hertl; C Jantschitsch; A Jung; U Just; C-D Klemke; U Lippert; T Luger; E Papadavid; H Pehamberger; A Ranki; R Stadler; W Sterry; I H Wolf; M Worm; J Zic; C C Zouboulis; U Hillen
Journal:  J Eur Acad Dermatol Venereol       Date:  2014-01       Impact factor: 6.166

Review 3.  Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).

Authors:  Henry K Wong; Anjali Mishra; Timothy Hake; Pierluigi Porcu
Journal:  Br J Haematol       Date:  2011-08-25       Impact factor: 6.998

4.  Predictors of response to extracorporeal photopheresis in advanced mycosis fungoides and Sézary syndrome.

Authors:  Laura Y McGirt; Christopher Thoburn; Allan Hess; Eric C Vonderheid
Journal:  Photodermatol Photoimmunol Photomed       Date:  2010-08       Impact factor: 3.135

5.  Single-Cell Profiling of Cutaneous T-Cell Lymphoma Reveals Underlying Heterogeneity Associated with Disease Progression.

Authors:  Nicholas Borcherding; Andrew P Voigt; Vincent Liu; Brian K Link; Weizhou Zhang; Ali Jabbari
Journal:  Clin Cancer Res       Date:  2019-02-04       Impact factor: 12.531

6.  Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome.

Authors:  Larisa J Geskin; Oleg E Akilov; Soonyou Kwon; Michael Schowalter; Simon Watkins; Theresa L Whiteside; Lisa H Butterfield; Louis D Falo
Journal:  Cancer Immunol Immunother       Date:  2017-12-04       Impact factor: 6.968

7.  Tumor-infiltrating and circulating granulocytic myeloid-derived suppressor cells correlate with disease activity and adverse clinical outcomes in mycosis fungoides.

Authors:  K V Argyropoulos; M Pulitzer; S Perez; P Korkolopoulou; M Angelopoulou; C Baxevanis; M L Palomba; M Siakantaris
Journal:  Clin Transl Oncol       Date:  2019-11-06       Impact factor: 3.405

Review 8.  Tregs and rethinking cancer immunotherapy.

Authors:  Tyler J Curiel
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

9.  Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma.

Authors:  Elisabetta Capriotti; Eric C Vonderheid; Christopher J Thoburn; Mariusz A Wasik; David W Bahler; Allan D Hess
Journal:  Leuk Lymphoma       Date:  2008-06

10.  Regulation gone wrong: a subset of Sézary patients have malignant regulatory T cells.

Authors:  Rachael A Clark
Journal:  J Invest Dermatol       Date:  2009-12       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.